EAM
Erste Asset Management Portfolio holdings
AUM
$11.9B
1-Year Return
22.95%
This Quarter Return
+22.83%
1 Year Return
+22.95%
3 Year Return
+112.82%
5 Year Return
+205.55%
10 Year Return
–
AUM
$3.61B
AUM Growth
+$682M
(+23%)
Cap. Flow
+$165M
Cap. Flow
% of AUM
4.58%
Top 10 Holdings %
Top 10 Hldgs %
17.47%
Holding
954
New
83
Increased
179
Reduced
131
Closed
34
Top Buys
| 1 |
Biogen
BIIB
|
+$35.3M |
| 2 |
Signet Jewelers
SIG
|
+$13.5M |
| 3 |
Microsoft
MSFT
|
+$12.7M |
| 4 |
Silicon Motion
SIMO
|
+$11M |
| 5 |
TJX Companies
TJX
|
+$11M |
Top Sells
| 1 |
Darden Restaurants
DRI
|
+$27.2M |
| 2 |
Tapestry
TPR
|
+$15.7M |
| 3 |
Ameriprise Financial
AMP
|
+$12.6M |
| 4 |
Abbott
ABT
|
+$9.4M |
| 5 |
Denali Therapeutics
DNLI
|
+$9.37M |
Sector Composition
| 1 | Technology | 27.61% |
| 2 | Healthcare | 21.59% |
| 3 | Consumer Discretionary | 15.04% |
| 4 | Industrials | 8.92% |
| 5 | Financials | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Analog Devices
ADI
$122B
| $718K | 0.02% |
5,000
| – | – |
|
352
Etsy
ETSY
$5.77B
| $718K | 0.02% |
3,918
+1,359
| +53% | +$249K |
|
353
Labcorp
LH
$23B
| $708K | 0.02% |
+4,074
| New | +$708K |
|
354
KALA BIO
KALA
$102M
| $705K | 0.02% |
2,102
| – | – |
|
355
Revolution Medicines
RVMD
$7.68B
| $703K | 0.02% |
+17,400
| New | +$703K |
|
356
Arch Capital
ACGL
$33.9B
| $681K | 0.02% |
+19,300
| New | +$681K |
|
357
Kinder Morgan
KMI
$58.8B
| $679K | 0.02% |
50,000
-139,000
| -74% | -$1.89M |
|
358
Coca-Cola
KO
$292B
| $675K | 0.02% |
12,434
+5,343
| +75% | +$290K |
|
359
Seres Therapeutics
MCRB
$200M
| $661K | 0.02% |
+1,350
| New | +$661K |
|
|
ITCI
360
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $655K | 0.02% |
21,000
| – | – |
|
361
Sangamo Therapeutics
SGMO
$157M
| $632K | 0.02% |
38,000
+2,000
| +6% | +$33.3K |
|
362
Arthur J. Gallagher & Co
AJG
$76.7B
| $620K | 0.02% |
5,100
-4,900
| -49% | -$595K |
|
|
QIWI
363
DELISTED
QIWI PLC
QIWI
| $617K | 0.02% |
60,000
-20,000
| -25% | -$206K |
|
|
KLRS
364
Kalaris Therapeutics, Inc. Common Stock
KLRS
$86.8M
| $607K | 0.02% |
+713
| New | +$607K |
|
365
Regenxbio
RGNX
$479M
| $604K | 0.02% |
13,000
| – | – |
|
366
Wells Fargo
WFC
$259B
| $587K | 0.02% |
19,711
+12,828
| +186% | +$382K |
|
|
IGMS
367
DELISTED
IGM Biosciences
IGMS
| $576K | 0.02% |
+6,500
| New | +$576K |
|
368
Avery Dennison
AVY
$13.1B
| $548K | 0.02% |
3,600
-2,910
| -45% | -$443K |
|
369
Stoke Therapeutics
STOK
$1.21B
| $544K | 0.02% |
+9,200
| New | +$544K |
|
370
Skyworks Solutions
SWKS
$11.2B
| $542K | 0.02% |
3,549
+1,869
| +111% | +$285K |
|
371
TC Energy
TRP
$53.9B
| $540K | 0.02% |
13,100
-2,500
| -16% | -$103K |
|
372
Zentalis Pharmaceuticals
ZNTL
$118M
| $534K | 0.01% |
+9,800
| New | +$534K |
|
373
FIVE9
FIVN
$2.06B
| $528K | 0.01% |
3,000
| – | – |
|
374
F5
FFIV
$18.4B
| $525K | 0.01% |
3,000
| – | – |
|
375
Revvity
RVTY
$10B
| $507K | 0.01% |
+3,600
| New | +$507K |
|